TOP10 reimbursement value in Poland – December 2023

?? Updated December 2023 #DGL bulletin data

?? At the end of 2023, the cumulative #reimbursement amount for the whole market stands at almost PLN 19.2 billion, which is 2.7 billion more than at the end of the previous year and than total reimbursement amount in 2022.

?? For the whole market the TOP10 remains unchanged, with #Keytruda on the 1st place, with PLN 556 million cumulative reimbursement amount in the current year, followed by #Opdivo and #Kaftrio.

?? For the outpatient list in the final stretch, #Xarelto took 3rd place on the podium, while #Forxiga dropped by 2 places and finishes in 5th. #Ozempic debuted at 10th place, with almost PLN 92 million cumulative reimbursement amount in the current year.

??For the #chemotherapy the cumulative reimbursement amount in the current year stands at almost PLN 565 million, which is 61 million more than in the same period of the previous year. The market share for TOP10 brands in chemotherapy is almost 52%. #Pelgraz and #Pegasys switched places - Pelgraz moved up to 4th place on the TOP10 list.

Yo can find more data in our IDA TOP10 report: https://app.powerbi.com/view?r=eyJrIjoiZGI3MDlkYWEtZDhmZi00MmIxLTlkNDctZTk3NjgyZWQyMjUyIiwidCI6IjFhYjJiNGUwLWE4ZmUtNGQ3OS1hY2Q1LTk2NzhlMThiN2IxOSIsImMiOjl9&embedImagePlaceholder=true

?#healthcare #drugs #medical #ochronazdrowia #opiekazdrowotna #medycyna #medicine #hta #refundacja #programylekowe #oncology #drugprogrammes #MZ #NFZ #htaconsulting #PowerBi #analysis #pharmacy #pharma #dataanalysis #foodstuffs #IDA #leki #data #terapia #change #obesity